This study focuses on people with advanced Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic characteristic called MTAP deletion. This type of lung cancer has already been treated with at least one previous therapy but has continued to progress. The cancer is either spread to other parts of the body (metastatic) or cannot be removed through surgery (unresectable).

The study will test a new medication called AMG 193, which is given as tablets taken by mouth. This research aims to understand how well AMG 193 works and how safe it is for patients at two different dose levels. The study consists of two parts, and doctors will monitor how patients respond to the treatment using special imaging tests like computed tomography (CT) or Magnetic Resonance Imaging (MRI).

During the study, researchers will track various aspects of the treatment’s effectiveness, including how many patients’ tumors shrink or disappear, how long the treatment benefits last, and how long patients survive without their disease getting worse. They will also collect information about any side effects that occur and measure the amount of medication in patients’ bodies. Additionally, patients will complete questionnaires about their symptoms and overall health throughout the study.